** Drug developer Amylyx Pharmaceuticals' AMLX.O shares fall 3.5% to $2.89

** Company posts Q4 net loss of $37.5 million compared with net income of $4.7 million a year ago

** AMLX closes its underwritten public offering of 19.7 million shares with net proceeds of about $65.5 million

** The offering extends the company's cash runway through the end of 2026

** In the last 12 months, AMLX has fallen 84%

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))